POTASSIUM CHLORIDE 0.3% W/V & GLUCOSE 5% W/V SOLUTION FOR INFUSION
Active substance(s): GLUCOSE MONOHYDRATE / POTASSIUM CHLORIDE / GLUCOSE MONOHYDRATE / POTASSIUM CHLORIDE / GLUCOSE MONOHYDRATE / POTASSIUM CHLORIDE
NAME OF THE MEDICINAL PRODUCT
Potassium Chloride 0.3% w/v & Glucose 5% w/v Solution for Infusion
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each ml contains 3.00 mg Potassium Chloride and 50.0 mg Glucose
Each 500 ml bottle contains 1.50 g Potassium Chloride and 25 g Glucose
Each 1000 ml bottle contains 3.00 g Potassium Chloride and 50 g Glucose
mmol/l: K +: 40 Cl -: 40
For the full list of excipients, see section 6.1.
Solution for infusion
Clear solution, free from visible particles.
3.5 – 6.0
Prevention and treatment of potassium depletion and/or hypokalaemia in cases where
supply of water and carbohydrates is required due to either restriction of the intake of
fluids and electrolytes or depletion by normal routes
Posology and method of administration
Doses may be expressed in terms of mEq or mmol of potassium, mass of potassium,
or mass of potassium salt:
1 g KCl = 525 mg of K + or 13.4 mEq or 13.4 mmol of K + and Cl 1 mmol K + = 39.1 mg K +.
The dosage of this solution depends on the age, weight, clinical and biological (acidbase balance) conditions of the patient, concomitant therapy and in particular the
patient’s hydration state.
The recommended dosage for the treatment of carbohydrates and fluid depletion is
- for adults: 500 ml to 3 litres/24 h
- for babies and children: 0 - 10 kg body weight: 100 ml/kg/24 h
10 - 20 kg body weight: 1000 ml + (50 ml/kg over 10 kg) /24 h
> 20 kg body weight: 1500 ml + (20 ml/kg over 20 kg)/24 h
The infusion rate should not exceed the patient’s glucose oxidation capacities in order
to avoid hyperglycaemia. Therefore the maximum dose ranges from 5 mg/kg/min for
adults to 10 - 18 mg/kg/min for babies and children depending on the age and the
total body mass.
Posology for prevention and treatment of potassium depletion
Adults, Older people and Adolescents
A typical dose of potassium for the prevention of hypokalaemia may be up to
50 mmol daily and similar doses may be adequate in mild potassium deficiency. The
maximal recommended dose of potassium is 2 to 3 mmol/kg/24 h.
When used for the treatment of hypokalaemia, the recommended dosage is 20 mmol
of potassium over 2 to 3 hours (i.e. 7-10 mmol/h) under ECG control.
The maximum recommended administration rate should not exceed 15-20 mmol/h.
Patients with renal impairment should receive lower doses.
In any case, the dosage given under “General Posology” should not be exceeded.
Use in Paediatric Population
When used in the treatment of hypokalaemia the recommended dosage is 0.3 – 0.5
mmol/kg/b.w./h. The dose has to be adjusted on frequently obtained lab values.
The maximum recommended dose of potassium is 2 to 3 mmol/kg/b.w./day.
The infusion rate and volume depends on the age, weight, clinical and metabolic
conditions of the patient, concomitant therapy and should be determined by the
consulting physician experienced in paediatric intravenous fluid therapy (see Section
Method of administration
Route of administration
The administration is performed by intravenous route using sterile and non-pyrogenic
Intravenous potassium should be administered via a large peripheral or central vein to
diminish the risk of causing sclerosis. If infused through a central vein, be sure the
catheter is not in the atrium or ventricle to avoid localised hyperkalaemia.
Solutions containing potassium should be administered slowly.
Rate of administration
As administered intravenously, potassium should not be given faster than 15 to 20
mmol/h to avoid dangerous hyperkalaemia.
Adequate urine flow must be ensured and careful monitoring of plasma-potassium
and other electrolyte concentrations is essential. Higher dosage or high speed infusion
must be performed under ECG control.
- Hyperchloremia and hyperkalaemia
- Severe renal insufficiency (with oliguria/anuria)
- Uncompensated cardiac failure
- Addison’s disease
The solution is also contraindicated in cases of uncompensated diabetes, other known
glucose intolerances (such as metabolic stress situations), hyperosmolar coma,
Special warnings and precautions for use
High volume infusion must be used under specific monitoring in patients with cardiac
or pulmonary failure.
Administration should be carried out under regular and careful surveillance. Regular
monitoring of clinical status, blood glucose level, plasma electrolyte concentrations,
plasma creatinine levels, BUN level, acid-base balance and ECG is essential in
patients receiving potassium therapy, particularly those with cardiac or renal
impairment. Adequate urine flow must be ensured and fluid balance should be
Potassium salts should be administered with considerable care to patients with cardiac
disease (e.g. myocardial infarction, cardiac arrhythmias) or conditions predisposing to
hyperkalemia such as renal or adrenocortical insufficiency, acute dehydration, or
extensive tissue destruction as occurs with severe burns.
In patients under digitalis therapy regular monitoring of the plasma potassium level is
Infusion of solutions containing glucose could be contraindicated in the first 24 hours
following head trauma and blood glucose concentration should be closely monitored
during intracranial hypertension episodes.
Administration of glucose containing solutions may lead to hyperglycaemia. In this
case, it is recommended not to use this solution after acute ischemic strokes as
hyperglycaemia has been implicated in increasing cerebral ischemic brain damage
and impairing recovery.
If hyperglycaemia occurs, rate of infusion should be adjusted or insulin administered.
In diabetic patients, the amount of infused glucose has to be taken into account and
insulin requirements may be modified.
During long term treatment, a convenient nutritive treatment supply must be given to
Potassium Chloride 0.3% w/v & Glucose 5% w/v Solution for Infusion contains
glucose derived from corn. It should be used with caution in patients with known corn
allergies (see section 4.8).
Newborns – especially those born premature and with low birth weight -are at
increased risk of developing hypo- or hyperglycaemia and therefore need close
monitoring during treatment with intravenous glucose solutions to ensure adequate
glycaemic control in order to avoid potential long term adverse effects.
Hypoglycaemia in the newborn can cause prolonged seizures, coma and brain
damage. Hyperglycaemia has been associated with intraventricular haemorrhage, late
onset bacterial and fungal infection, retinopathy of prematurity, necrotizing
enterocolitis, bronchopulmonary dysplasia, prolonged length of hospital stay, and
In order to avoid potentially fatal over infusion of intravenous fluids to the neonate,
special attention needs to be paid to the method of administration. When using a
syringe pump to administer intravenous fluids or medicines to neonates, a bottle of
fluid should not be left connected to the syringe.
When using an infusion pump all clamps on the intravenous administration set must
be closed before removing the administration set from the pump, or switching the
pump off. This is required regardless of whether the administration set has an anti
free flow device.
The intravenous infusion device and administration equipment must be frequently
Plasma electrolyte concentrations should be closely monitored in the paediatric
population as this population may have impaired ability to regulate fluids and
electrolytes. The infusion of hypotonic fluids together with the non-osmotic secretion
of ADH may result in hyponatraemia. Hyponatraemia can lead to headache, nausea,
seizures, lethargy, coma, cerebral oedema and death, therefore acute symptomatic
hyponatraemic encephalopathy is considered a medical emergency.
Interaction with other medicinal products and other forms of interaction
Solutions containing potassium should be used with caution, in patients receiving
drugs that increase plasma-potassium concentrations (e.g. potassium-sparing
diuretics, ACE inhibitors, Angiotensin II receptors antagonists, ciclosporin,
tacrolimus and drugs that contain potassium).
The pharmacological effect of digitalis glycosides (digoxin and methyldigoxin) and
antiarrhythmic agents (such as quinidine, hydroquinidine, procainamide) can be
altered as a function of blood potassium levels:
-Digitalis: hyperkalaemia reduces the therapeutic action of these drugs whereas
hypokalaemia can cause digitalis toxicity.
-Antiarrhythmic agents: hyperkalaemia increases their antiarrhythmic effects and
hypokalaemia reduces their efficacy.
Glucose should not be administered through the same infusion equipment as whole
blood, as haemolysis and clumping can occur.
Fertility, pregnancy and lactation
Hyperkalaemic and hypokalaemic serum levels lead to impaired cardiac function of
the maternal and foetal hearts. Therefore, maternal electrolyte levels must be
As long as the maternal electrolyte serum levels are kept within the physiological
range, there are no potential concerns regarding administration of Potassium Chloride
0.3% w/v & Glucose 5% w/v Solution for Infusion during pregnancy and lactation
Effects on ability to drive and use machines
Adverse reactions may be associated to the technique of administration, including
febrile response, infection at the site of injection, local pain or reaction, vein
irritation, venous thrombosis or phlebitis extending from the site of injection,
extravasation, and hypervolemia.
In case of undesirable effect(s), the infusion must be discontinued.
Anaphylactic reaction, hypersensitivity, and chills have also been reported.1
Reported for similar solutions containing dextrose.
System Organ Class
Symptoms (LLT terms
Immune system disorders
Metabolism and nutrition
Skin and subcutaneous
General disorders and
Febrile reaction, Fever
Infection at site of injection
Tabulated list of adverse reactions
(*) cannot be estimated from the available data
(**) Potential manifestation in patients with allergy to corn, see section 4.4.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is
important. It allows continued monitoring of the benefit/risk balance of the medicinal
product. Healthcare professionals are asked to report any suspected adverse reactions
via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.
Excessive administration of potassium may lead to the development of
hyperkalaemia, especially in patients with renal impairment. Symptoms include
paresthesia of the extremities, muscle weakness, paralysis, cardiac arrhythmias, heart
block, cardiac arrest, and mental confusion.
One of the important indicators of potassium toxicity is ECG changes including tall,
peaked T-waves, depression of S-T segment, disappearance of the P-wave,
prolongation of the Q-T interval, and widening and slurring of the QRS complex.
Treatment of hyperkalaemia involves the administration of calcium, insulin or sodium
bicarbonate, and exchange resins or dialysis.
Excessive administration of chloride salts may cause a loss of bicarbonate with an
In the event of accidental over infusion, treatment should be discontinued and the
patient should be observed for the appropriate signs and symptoms related to the drug
administered. The relevant symptomatic and supportive measures should be provided
Pharmacotherapeutic group: Blood substitutes and perfusion solutions; electrolytes
with carbohydrates, ATC code: B05BB02
Potassium Chloride 0.3% w/v & Glucose 5% w/v is a hypertonic solution of
electrolytes and glucose, with an approximate osmolarity of 358 mOsm/l.
The pharmacodynamic properties of this solution are those of its components
(potassium, chloride and glucose).
Potassium is predominantly an intracellular cation, primarily found in muscle; only
about 2% is present in the extracellular fluid. It is essential for numerous metabolic
and physiological processes including nerve conduction, muscle contraction, and
Chloride is mainly an extracellular anion. Intracellular chloride is in high
concentration in red blood cells and gastric mucosa.
Glucose is the principal source of energy in cellular metabolism.
The pharmacokinetic properties of Potassium Chloride 0.3% w/v & Glucose 5% w/v
are those of its components (potassium, chloride and glucose).
Intravenous administration of this solution provides an immediate supply of
electrolytes and glucose to blood.
Factors influencing potassium transfer between intracellular and extracellular fluid
such as acid-base disturbances can distort the relationship between plasma
concentrations and total body stores. Potassium is excreted mainly by the kidneys; it
is secreted in the distal tubules in exchange for sodium or hydrogen ions.
The capacity of the kidneys to conserve potassium is poor and some urinary excretion
of potassium continues even when there is severe depletion. Some potassium is
excreted in the faeces and small amounts may also be excreted in sweat.
The two main metabolic pathways of glucose are gluconeogenesis (energy storage)
and glycogenolysis (energy release). Glucose metabolism is regulated by insulin.
Preclinical safety data
Preclinical safety data of Potassium Chloride 0.3% w/v & Glucose 5% w/v Solution
for Infusion in animals are not relevant since potassium chloride and glucose are
physiological components of the body.
Toxic effects are not to be expected if serum electrolytes are kept within
List of excipients
Water for injections
Sodium hydroxide (for pH adjustment)
Hydrochloric acid (for pH adjustment)
Incompatibility of the medicinal product to be added to Potassium Chloride 0.3% w/v
& Glucose 5% w/v must be assessed before addition.
In the absence of compatibility studies, this solution must not be mixed with other
It is the responsibility of the physician to judge the incompatibility of an additive
medication with the Potassium Chloride 0.3% w/v & Glucose 5% w/v Solution for
Infusion by checking for eventual colour change and/or eventual precipitate, insoluble
complexes or the appearance of crystals. The Instructions for Use of the medication to
be added must be consulted.
Before adding a drug, verify that it is soluble and/or stable in water at the pH of
Potassium Chloride 0.3% w/v & Glucose 5% w/v Solution for Infusion (pH: 3.5 to
As a guidance, the following medications are incompatible with the Potassium
Chloride 0.3% w/v & Glucose 5% solution (non-exhaustive listing):
- Amphotericin B
Glucose should not be administered through the same infusion equipment as whole
blood, as haemolysis and clumping can occur.
Those additives known to be incompatible should not be used.
Shelf life after first opening:
Stability of the product after first opening has not been tested, therefore, the product
has to be used immediately after first opening.
In-use shelf life (additives):
Chemical and physical stability of any additive medication at the pH of the
Potassium Chloride 0.3% w/v & Glucose 5% w/v Solution for Infusion should be
established prior to use.
From a microbiological point of view, the mixtures of this medicinal product with
other medicinal products must be used immediately unless the mixture has taken
place under controlled and validated aseptic conditions. If not used immediately, inuse storage times and conditions are the responsibility of the user.
Special precautions for storage
This medicinal product does not require any special storage conditions.
Nature and contents of container
Potassium Chloride 0.3% w/v & Glucose 5% w/v is available in 500 ml and 1000 ml
low-density polyethylene bottles as primary packaging closed with a polyolefin cap
containing a polyisoprene rubber stopper. It is supplied in packs of 10 bottles.
Not all pack sizes may be marketed.
Special precautions for disposal
Potassium Chloride 0.3% w/v & Glucose 5% w/v is a ready to use solution.
It is for single use only. Any unused solution should be discarded.
Use only if the solution is clear, without visible particles and if the container is
Any unused product or waste material should be disposed of in accordance with local
MARKETING AUTHORISATION HOLDER
Fresenius Kabi Limited
Cestrian Court, Eastgate Way,
Manor Park, Runcorn,
Cheshire, WA7 1NT
MARKETING AUTHORISATION NUMBER(S)
DATE OF FIRST AUTHORISATION/RENEWAL OF THE
DATE OF REVISION OF THE TEXT
Source: Medicines and Healthcare Products Regulatory Agency
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.